Literature DB >> 25633490

Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.

Jie Xia1, Ermias Lemma Tilahun, Eyob Hailu Kebede, Terry-Elinor Reid, Liangren Zhang, Xiang Simon Wang.   

Abstract

Histone deacetylases (HDACs) are an important class of drug targets for the treatment of cancers, neurodegenerative diseases, and other types of diseases. Virtual screening (VS) has become fairly effective approaches for drug discovery of novel and highly selective histone deacetylase inhibitors (HDACIs). To facilitate the process, we constructed maximal unbiased benchmarking data sets for HDACs (MUBD-HDACs) using our recently published methods that were originally developed for building unbiased benchmarking sets for ligand-based virtual screening (LBVS). The MUBD-HDACs cover all four classes including Class III (Sirtuins family) and 14 HDAC isoforms, composed of 631 inhibitors and 24609 unbiased decoys. Its ligand sets have been validated extensively as chemically diverse, while the decoy sets were shown to be property-matching with ligands and maximal unbiased in terms of "artificial enrichment" and "analogue bias". We also conducted comparative studies with DUD-E and DEKOIS 2.0 sets against HDAC2 and HDAC8 targets and demonstrate that our MUBD-HDACs are unique in that they can be applied unbiasedly to both LBVS and SBVS approaches. In addition, we defined a novel metric, i.e. NLBScore, to detect the "2D bias" and "LBVS favorable" effect within the benchmarking sets. In summary, MUBD-HDACs are the only comprehensive and maximal-unbiased benchmark data sets for HDACs (including Sirtuins) that are available so far. MUBD-HDACs are freely available at http://www.xswlab.org/ .

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633490      PMCID: PMC4677826          DOI: 10.1021/ci5005515

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  64 in total

Review 1.  Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.

Authors:  C A Hassig; S L Schreiber
Journal:  Curr Opin Chem Biol       Date:  1997-10       Impact factor: 8.822

2.  HDAC6 is a target for protection and regeneration following injury in the nervous system.

Authors:  Mark A Rivieccio; Camille Brochier; Dianna E Willis; Breset A Walker; Melissa A D'Annibale; Kathryn McLaughlin; Ambreena Siddiq; Alan P Kozikowski; Samie R Jaffrey; Jeffery L Twiss; Rajiv R Ratan; Brett Langley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

3.  Identification of novel SIRT3 inhibitor scaffolds by virtual screening.

Authors:  Heikki S Salo; Tuomo Laitinen; Antti Poso; Elina Jarho; Maija Lahtela-Kakkonen
Journal:  Bioorg Med Chem Lett       Date:  2013-03-16       Impact factor: 2.823

4.  NRLiSt BDB, the manually curated nuclear receptors ligands and structures benchmarking database.

Authors:  Nathalie Lagarde; Nesrine Ben Nasr; Aurore Jérémie; Hélène Guillemain; Vincent Laville; Taoufik Labib; Jean-François Zagury; Matthieu Montes
Journal:  J Med Chem       Date:  2014-03-25       Impact factor: 7.446

Review 5.  Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

Authors:  Andre Fischer
Journal:  Neuropharmacology       Date:  2014-01-31       Impact factor: 5.250

6.  Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.

Authors:  Lin Gao; Maria A Cueto; Fred Asselbergs; Peter Atadja
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

7.  Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.

Authors:  Hao Tang; Xiang S Wang; Xi-Ping Huang; Bryan L Roth; Kyle V Butler; Alan P Kozikowski; Mira Jung; Alexander Tropsha
Journal:  J Chem Inf Model       Date:  2009-02       Impact factor: 4.956

8.  Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Authors:  Nancy Zhou; Oscar Moradei; Stephane Raeppel; Silvana Leit; Sylvie Frechette; Frederic Gaudette; Isabelle Paquin; Naomy Bernstein; Giliane Bouchain; Arkadii Vaisburg; Zhiyun Jin; Jeff Gillespie; James Wang; Marielle Fournel; Pu T Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Aihua Lu; Jubrail Rahil; A Robert MacLeod; Zuomei Li; Jeffrey M Besterman; Daniel Delorme
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

9.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Authors:  Marielle Fournel; Claire Bonfils; Yu Hou; Pu Theresa Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Jianhong Liu; Ai-Hua Lu; Nancy Z Zhou; Marie-France Robert; Jeffrey Gillespie; James J Wang; Hélène Ste-Croix; Jubrail Rahil; Sylvain Lefebvre; Oscar Moradei; Daniel Delorme; A Robert Macleod; Jeffrey M Besterman; Zuomei Li
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

10.  HDAC2 negatively regulates memory formation and synaptic plasticity.

Authors:  Ji-Song Guan; Stephen J Haggarty; Emanuela Giacometti; Jan-Hermen Dannenberg; Nadine Joseph; Jun Gao; Thomas J F Nieland; Ying Zhou; Xinyu Wang; Ralph Mazitschek; James E Bradner; Ronald A DePinho; Rudolf Jaenisch; Li-Huei Tsai
Journal:  Nature       Date:  2009-05-07       Impact factor: 49.962

View more
  10 in total

1.  A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.

Authors:  Huabin Hu; Jie Xia; Dongmei Wang; Xiang Simon Wang; Song Wu
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

2.  The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.

Authors:  Jie Xia; Huabin Hu; Wenjie Xue; Xiang Simon Wang; Song Wu
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 3.  Benchmarking Data Sets from PubChem BioAssay Data: Current Scenario and Room for Improvement.

Authors:  Viet-Khoa Tran-Nguyen; Didier Rognan
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

Review 4.  The Roles of the NLRP3 Inflammasome in Neurodegenerative and Metabolic Diseases and in Relevant Advanced Therapeutic Interventions.

Authors:  Rameez Hassan Pirzada; Nasir Javaid; Sangdun Choi
Journal:  Genes (Basel)       Date:  2020-01-27       Impact factor: 4.096

5.  A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening.

Authors:  Hongwei Jin; Jie Xia; Zhenming Liu; Xiang Simon Wang; Liangren Zhang
Journal:  Chem Biol Drug Des       Date:  2021-01-16       Impact factor: 2.817

6.  Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches.

Authors:  Xiaocong Pang; Baoyue Zhang; Guangyan Mu; Jie Xia; Qian Xiang; Xia Zhao; Ailin Liu; Guanhua Du; Yimin Cui
Journal:  RSC Adv       Date:  2018-10-10       Impact factor: 4.036

7.  Virtual screening and experimental validation of novel histone deacetylase inhibitors.

Authors:  Yan-Xin Huang; Jian Zhao; Qiu-Hang Song; Li-Hua Zheng; Cong Fan; Ting-Ting Liu; Yong-Li Bao; Lu-Guo Sun; Li-Biao Zhang; Yu-Xin Li
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-21       Impact factor: 2.483

Review 8.  Decoys Selection in Benchmarking Datasets: Overview and Perspectives.

Authors:  Manon Réau; Florent Langenfeld; Jean-François Zagury; Nathalie Lagarde; Matthieu Montes
Journal:  Front Pharmacol       Date:  2018-01-24       Impact factor: 5.810

Review 9.  Key Topics in Molecular Docking for Drug Design.

Authors:  Pedro H M Torres; Ana C R Sodero; Paula Jofily; Floriano P Silva-Jr
Journal:  Int J Mol Sci       Date:  2019-09-15       Impact factor: 5.923

10.  A prospective compound screening contest identified broader inhibitors for Sirtuin 1.

Authors:  Shuntaro Chiba; Masahito Ohue; Anastasiia Gryniukova; Petro Borysko; Sergey Zozulya; Nobuaki Yasuo; Ryunosuke Yoshino; Kazuyoshi Ikeda; Woong-Hee Shin; Daisuke Kihara; Mitsuo Iwadate; Hideaki Umeyama; Takaaki Ichikawa; Reiji Teramoto; Kun-Yi Hsin; Vipul Gupta; Hiroaki Kitano; Mika Sakamoto; Akiko Higuchi; Nobuaki Miura; Kei Yura; Masahiro Mochizuki; Chandrasekaran Ramakrishnan; A Mary Thangakani; D Velmurugan; M Michael Gromiha; Itsuo Nakane; Nanako Uchida; Hayase Hakariya; Modong Tan; Hironori K Nakamura; Shogo D Suzuki; Tomoki Ito; Masahiro Kawatani; Kentaroh Kudoh; Sakurako Takashina; Kazuki Z Yamamoto; Yoshitaka Moriwaki; Keita Oda; Daisuke Kobayashi; Tatsuya Okuno; Shintaro Minami; George Chikenji; Philip Prathipati; Chioko Nagao; Attayeb Mohsen; Mari Ito; Kenji Mizuguchi; Teruki Honma; Takashi Ishida; Takatsugu Hirokawa; Yutaka Akiyama; Masakazu Sekijima
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.